BioNTech SE (BNTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yaron Werber ...

Operator Welcome to BioNTech's third quarter 2024 earnings call. I would like to hand the call over to Michael Horowicz ...

Driven by the early approval of its updated COVID-19 vaccine, BioNTech far exceeded analysts’ expectations in the third ...

Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...

German drugmaker BioNTech on Monday lowered its guidance for full-year revenue, citing COVID-19 uptake and price levels, ...

BioNTech's Q3 revenue surged to €1.244 billion, reflecting early COVID-19 vaccine approvals. Net profit rose to €198.1 million, and full-year guidance adjusted downward.

Presented clinical data for multiple assets across modalities, including bispecific antibody candidate BNT327/PM8002 and mRNA cancer vaccine ...

Sen. Rand Paul pointed to CDC guidance on child COVID-19 vaccinations, suggesting that people are "hesitant to believe" the ...

In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three ...

1-lineage omicron variants of the coronavirus, or SARS-CoV-2. The options include the mRNA vaccines from Pfizer/BioNTech and ...

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...

Astellas' first-in-class CLDN18.2 drug Vyloy has cleared the FDA. After a positive phase 3 readout, Otsuka is targeting an ...